Pharmacokinetics of Benzo[a]Pyrene: Impact of Diet

Early Phase 1CompletedNCT03802721

Oregon State University7 enrolled

Overview

Evaluation of the pharmacokinetics for \[14C\]-benzo\[a\]pyrene (\[14C\]-BaP) and metabolites in plasma and urine over 48 hours following a 50 ng dose (5.4 nCi) alone, following 7 days' consumption of Brussels sprouts, and following 7 days' consumption of a supplement containing 3,3'-diindolylmethane (DIM).

The pharmacokinetics for \[14C\]-BaP and metabolites will be assessed by UHLPC-Accelerator Mass Spectrometry (AMS, Lawrence Livermore National Laboratory) in plasma and urine collected over 48 hours following oral doses of 50 ng dose (5.4 nCi) alone, following 7 days' consumption of Brussels sprouts, and following 7 days' consumption of a supplement containing 3,3'-diindolylmethane (DIM). The investigators hypothesize that pre-administration of Brussels sprouts or DIM will alter \[14C\]-BaP metabolism and increase the rate of elimination consistent with predictions based on a previously developed Physiologically-Based Pharmacokinetic (PBPK) model for BaP. Briefly, this hypothesis will be tested by dosing individuals with 50 ng \[14C\]-BaP alone and, following a 3-week washout period, ingestion of about 50 g Brussels sprouts or 300 mg of 3,3'-diindolylmethane (DIM) supplement for 7 days prior to the \[14C\]-BaP micro-dose. The impact of the supplement and the whole food will be assessed with respect to alterations in uptake from the GI tract, metabolism and rate of elimination. The consumption of cruciferous vegetables will be assessed at the beginning of the study by completion of a dietary questionnaire to examine typical eating patterns in the previous 3 months and by collection and extraction of blood and urine to assay for DIM by LC/ESI-MS/MS-SRM). In addition, for each phase, urine will be assayed for DIM as an estimate of crucifer or DIM supplement intake. In preclinical and clinical studies, administration of Brussels sprouts or DIM impacts the activity of the same enzymes responsible for the phase 1 (CYP1A1 and CYP1B1) and phase 2 enzymes (GSTM1, UGT, SULT). Monitoring changes in β-estradiol metabolites will confirm the mechanism of alteration in the metabolic profile of \[14C\]-BaP. Metabolite profiles and kinetics of elimination are predicted to be consistent with a BaP physiologically based pharmacokinetic (PBPK) model developed by Pacific Northwest National Laboratory (PNNL). A non-smoker, not exposed occupationally, receives 270-700 ng of BaP daily; about 95% dietary. The WHO has set an estimated safe daily lifetime (70 year/70 Kg individual, cancer endpoint) exposure to BaP of 42-350 ng. This protocol represents de minimus risk.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Environmental Exposure

Interventions

[14C]-benzo[a]pyreneDRUG

Oral micro-dose (50 ng) (5.4 nCi)

Brussels sprouts before 50 ng doseDRUG

Brussels sprouts for 7 days before 50 ng (5.4 nCi) dose of BaP

DIM supplement before 50 ng doseDRUG

DIM supplement for 7 days before 50 ng (5.4 nCi) dose of BaP and coadministration with DIM supplement

Eligibility

Sex: ALLMin age: 21 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age 21-65 (inclusive) * If female, must be post-menopausal or have had surgical sterilization to eliminate any possibility for fetal exposure * Willing to defer blood donation for one month before, throughout, and one month after completion of study activities * Willing to avoid consuming cruciferous vegetables, I3C or DIM supplements, smoked or cured meat or cheeses, or charcoal-grilled meats for 2 weeks prior to and during each study cycle (gas grilled foods acceptable) * Health history review and physical assessment showing general good health, as determined by study physician. Acceptable physical exam may have been conducted as part of protocol 8233 or 8554 if subject has not had significant changes in health status. Exclusion Criteria: * Smoker (tobacco or other substances) or use of smokeless tobacco in past 3 months or living with smoker * Regular use of medications that affect gut motility or nutrient absorption (e.g. cholestyramine, sucralfate, orlistat, pro- or anti-motility agents) * History of gastrointestinal surgery (e.g. bariatric surgery, cholecystectomy) or gastrointestinal disorder (Crohn's disease, celiac disease, IBS, or colitis) * Current or history of kidney or liver disease * Prior high-dose 14C exposure from medical tests. (micro-dose 14C exposure not exclusionary) * Occupational PAH exposure (e.g. roofers, asphalt pavers, fire-fighters, etc.) * Regular use of indole-3-carbinol or DIM dietary supplements * Allergy or intolerance to Brussels sprouts or similar foods

Locations (1)

Oregon State University

Corvallis, Oregon, United States

Outcomes

Primary Outcomes

Peak Plasma Concentration of 14C-BaP Cmax

Determination of highest concentration of 14C-BaP in plasma. Blood samples collected at 0 (baseline), 0.25, 0.5, 1, 2, 3, 4, 8, 24, and 48 hour after dosing. All time points were used to determine Cmax.

Time frame: 0-48 hours for each of 3 dosing cycles, with a washout period of 3 weeks between each dosing cycle

Secondary Outcomes

Time at Highest Plasma Concentration of 14C-BaP Tmax

Determination of time at which plasma concentration of 14C-BaP is highest. Blood samples collected at 0 (baseline), 0.25, 0.5, 1, 2, 3, 4, 8, 24, and 48 hour after dosing. All time points were used to determine Tmax.

Time frame: 0-48 hours for each of 3 dosing cycles, with a washout period of 3 weeks between each dosing cycle

Area Under Plasma Concentration of 14C-BaP Versus Time Curve AUC

Integration of concentration of 14C-BaP in plasma over time. Blood samples collected at 0 (baseline), 0.25, 0.5, 1, 2, 3, 4, 8, 24, and 48 hour after dosing. All time points were used to determine AUC.

Time frame: 0-48 hours for each of 3 dosing cycles, with a washout period of 3 weeks between each dosing cycle

Rate of Elimination of 14C-BaP (Half Life)

Determination of constants for rate of elimination of 14C-BaP from plasma. Blood samples collected at 0 (baseline), 0.25, 0.5, 1, 2, 3, 4, 8, 24, and 48 hour after dosing. All time points were used to determine half-life.

Time frame: 0-48 hours for each of 3 dosing cycles, with a washout period of 3 weeks between each dosing cycle

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.